Analysts Set TScan Therapeutics, Inc. (NASDAQ:TCRX) PT at $9.33

Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) have received an average rating of “Buy” from the six brokerages that are currently covering the company, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $9.33.

Several equities analysts have recently commented on the company. Morgan Stanley reiterated an “overweight” rating and set a $10.00 target price on shares of TScan Therapeutics in a research note on Friday. Wedbush reiterated an “outperform” rating and set a $7.00 target price on shares of TScan Therapeutics in a research note on Wednesday, March 5th. HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of TScan Therapeutics in a research note on Thursday, March 6th. Needham & Company LLC reduced their price objective on TScan Therapeutics from $11.00 to $9.00 and set a “buy” rating on the stock in a research note on Wednesday, March 5th. Finally, Barclays reduced their price objective on TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating on the stock in a research note on Friday, March 7th.

Institutional Investors Weigh In On TScan Therapeutics

Large investors have recently added to or reduced their stakes in the stock. State Street Corp increased its position in TScan Therapeutics by 24.4% in the third quarter. State Street Corp now owns 756,499 shares of the company’s stock worth $3,767,000 after buying an additional 148,414 shares during the period. abrdn plc increased its position in TScan Therapeutics by 137.8% in the fourth quarter. abrdn plc now owns 883,704 shares of the company’s stock worth $2,686,000 after buying an additional 512,049 shares during the period. Geode Capital Management LLC increased its position in TScan Therapeutics by 8.1% in the third quarter. Geode Capital Management LLC now owns 973,466 shares of the company’s stock worth $4,849,000 after buying an additional 72,967 shares during the period. Stifel Financial Corp increased its position in TScan Therapeutics by 3.9% in the third quarter. Stifel Financial Corp now owns 99,133 shares of the company’s stock worth $494,000 after buying an additional 3,733 shares during the period. Finally, XTX Topco Ltd acquired a new stake in TScan Therapeutics in the third quarter worth $112,000. 82.83% of the stock is owned by institutional investors and hedge funds.

TScan Therapeutics Stock Down 2.8 %

Shares of NASDAQ:TCRX opened at $1.74 on Friday. The company has a quick ratio of 9.56, a current ratio of 9.56 and a debt-to-equity ratio of 0.13. TScan Therapeutics has a 52-week low of $1.71 and a 52-week high of $9.69. The company has a 50 day moving average of $2.28 and a two-hundred day moving average of $3.85. The company has a market capitalization of $98.47 million, a price-to-earnings ratio of -1.64 and a beta of 0.91.

TScan Therapeutics (NASDAQ:TCRX) last released its earnings results on Wednesday, March 5th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.02). The business had revenue of $0.67 million for the quarter, compared to analysts’ expectations of $1.43 million. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. As a group, analysts forecast that TScan Therapeutics will post -1.12 earnings per share for the current fiscal year.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.